Molecular Partners (NASDAQ:MOLN) Stock Price Up 1.5% - What's Next?

Key Points

• Molecular Partners' shares increased by 1.5% to $3.70, despite a decline in trading volume of 19% compared to the average session.
• JPMorgan Chase & Co. lowered the price target for the stock from $4.50 to $4.00 and maintained a "neutral" rating, while the consensus target price remains at $8.00.
• The company reported a quarterly loss of ($0.67) EPS, missing the consensus estimate of ($0.53), and analysts predict a full-year EPS of -1.93.

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN - Get Free Report) shares traded up 1.5% during trading on Thursday . The company traded as high as $3.70 and last traded at $3.70. 4,160 shares changed hands during mid-day trading, a decline of 19% from the average session volume of 5,110 shares. The stock had previously closed at $3.64.

Wall Street Analysts Forecast Growth

Separately, JPMorgan Chase & Co. dropped their price target on Molecular Partners from $4.50 to $4.00 and set a "neutral" rating for the company in a research note on Wednesday, September 3rd. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, Molecular Partners has a consensus rating of "Buy" and an average price target of $8.00.

Molecular Partners Stock Performance

The business has a 50 day moving average price of $3.71 and a two-hundred day moving average price of $3.83. The company has a market cap of $150.25 million, a P/E ratio of -1.79 and a beta of 1.10.

Molecular Partners (NASDAQ:MOLN - Get Free Report) last announced its quarterly earnings data on Monday, August 25th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.14). As a group, research analysts expect that Molecular Partners AG Sponsored ADR will post -1.93 EPS for the current year.

Molecular Partners Company Profile

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.